Completion of the Galapagos ulcerative colitis phase II trial increased the phase transition success rate (PTSR) score of the inhibitor SIK2 / SIK3 GLPG-3970 to 38% as of July 2.
PTSR is the probability, expressed as a percentage, that a drug will successfully pass from one stage of development to the next. The status of the Phase II trial (NCT04577794) on ClinicalTrials.gov was changed to “completed” on June 30, which increased the drug’s PTSR score by 9 points. PTSR is one of the metrics used to calculate a drug’s likelihood of approval (LoA), which also increased three points to 13% after this trial ended.
GLPG-3970 is the most advanced active in the Company’s Toledo program focused on candidates that target salt-inducible kinases (SIKs). The SIK3 inhibitor GLPG-4399 is under investigation in a phase I trial (NCT04653467), while others are still in preclinical studies. The Ulcerative Colitis Phase II study is one of five proof-of-concept trials with GLPG-3970, which is designed to stimulate anti-inflammatory cytokines and inhibit pro-inflammatory cytokines. Other inflammatory disorders for which GLPG-3970 is being investigated include psoriasis, rheumatoid arthritis, systemic lupus erythematosus, and primary Sjogren’s syndrome. In accordance with its 1Q report, Galapagos intends to continue its development plans in 2H based on the results of these trials.
The LoA score, which is calculated by GlobalData analysis using a combination of machine learning and a proprietary algorithm, as well as the PTSR can be calculated for a drug taking into account characteristics such as therapeutic area, indication and type of molecule.
Manasi Vaidya is associate editor of the investigative journalism team at Clinical Trials Arena’s parent company, GlobalData. A version of this article originally appeared on the Insights module of the Pharmaceutical Intelligence Center of GlobalData. To access more articles like this, visit GlobalData.